Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma

A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors

(2014) E. Angevin et al.   CLINICAL CANCER RESEARCH

A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma

(2013) Peter M. Voorhees et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Phase I, Open-Label Study of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease

(2013) R. Kurzrock et al.   CLINICAL CANCER RESEARCH

Interleukin-6 and JAK2/STAT3 signaling mediate the reversion of dexamethasone resistance after dexamethasone withdrawal in 7TD1 multiple myeloma cells

(2013) Tuoen Liu et al.   LEUKEMIA RESEARCH

Castleman's Disease: From Basic Mechanisms to Molecular Therapeutics

(2011) H. E. El-Osta et al.   ONCOLOGIST

Siltuximab, a Novel Anti–Interleukin-6 Monoclonal Antibody, for Castleman's Disease

(2010) Frits van Rhee et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death

(2009) Peter M. Voorhees et al.   BRITISH JOURNAL OF HAEMATOLOGY

A High-Affinity Fully Human Anti-IL-6 mAb, 1339, for the Treatment of Multiple Myeloma

(2009) M. Fulciniti et al.   CLINICAL CANCER RESEARCH

Proteasome inhibitors in the treatment of multiple myeloma

(2009) J J Shah et al.   LEUKEMIA

Tumour cell survival signalling by the ERK1/2 pathway

(2008) K Balmanno et al.   CELL DEATH AND DIFFERENTIATION

Treatment of newly diagnosed myeloma

(2008) A Palumbo et al.   LEUKEMIA